Cover Introduction ProSure Clinical Studies ... - Abbott Nutrition

Weight gain is associated with improved quality of life in patients with cancercachexia consuming an energy and protein dense, high n-3 fatty acid oral supplementCovervon Meyenfeldt M, Ferguson M, Voss A, Fearon K, Moses A, van Geenen R, Gouma DJ, Roy A, Giacosa A, van Gossum A, Tisdale MProc Am Soc Clin Oncol. 2002;21:385AIntroductionProSureClinical StudiesSupportingPublicationsIn a multicenter, randomized, double-blind, controlled trial, cachecticpatients with pancreatic cancer were randomized to consume twoservings of an energy and protein dense oral supplement enrichedwith n-3 fatty acids or an isocaloric, isonitrogenous control. Bodyweight, quality of life, and grip strength were measured at baselineand after 8 weeks.ObjectiveTo evaluate the effect of an energy and protein dense oral supplementenriched with n-3 fatty acids (ProSure) on body weight and quality oflife in cachectic patients with pancreatic cancer.Study Design• Study Population: Pancreatic (n = 200; ProSure = 95,control = 105)• Length of Study: 8 weeks• Intervention: 2 servings/day ProSure (240 mL/serving) orisocaloric, isonitrogenous controlOutcomesCompared to the control group, weight change in the ProSure groupcorrelated significantly with changes in:• EQ-5D index, (r = 0.46, P = 0.001)• EQ-5D vas, (r = 0.38, P = 0.01)• Physical functioning domain of QLQ-C30 (r = 0.33, P = 0.022)• Grip strength (r = 0.38, P = 0.009)Study ConclusionsIn patients with advanced pancreatic cancer taking ProSure,weight gain was associated with improvements in quality of lifeand grip strength.EPA -eicosapentaenoic acid